Skip to main content
Loading

IN8bio

February 26, 2024
Gene/Cell Therapy
IN8bio
IN8bio, a clinical-stage biopharmaceutical company, focuses on gamma-delta T cell product candidates for solid and liquid tumors. These T cells, naturally differentiating between healthy and diseased tissue, act as a bridge between innate and adaptive immunity, contributing to tumor killing, immune cell recruitment, and activation. IN8bio utilizes its DeltEx platform, employing allogeneic, autologous, iPSC, and genetically modified cell therapies. With expertise in gamma-delta T cell biology and proprietary genetic engineering, the company aims to identify and eradicate tumor cells.
Testimonials

Double Helix


 

Supporting Bank Sponsor


 

Premier Sponsors

Conference Sponsors


 

Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.

SIGN UP